ZIOPHARM Oncology Stock Forecast, Price & News

-0.09 (-3.93 %)
(As of 08/4/2021 03:26 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume39,780 shs
Average Volume1.30 million shs
Market Capitalization$474.14 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOPHARM Oncology logo

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.78 out of 5 stars

Medical Sector

777th out of 1,309 stocks

Pharmaceutical Preparations Industry

384th out of 646 stocks

Analyst Opinion: 3.2Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

Is ZIOPHARM Oncology a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ZIOPHARM Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZIOP, but not buy additional shares or sell existing shares.
View analyst ratings for ZIOPHARM Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than ZIOPHARM Oncology?

Wall Street analysts have given ZIOPHARM Oncology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ZIOPHARM Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for ZIOPHARM Oncology

How can I listen to ZIOPHARM Oncology's earnings call?

ZIOPHARM Oncology will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. During the same quarter in the prior year, the business posted ($0.09) earnings per share.
View ZIOPHARM Oncology's earnings history

How has ZIOPHARM Oncology's stock been impacted by Coronavirus?

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZIOP shares have decreased by 11.8% and is now trading at $2.24.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZIOP?

3 brokerages have issued 12 month target prices for ZIOPHARM Oncology's stock. Their forecasts range from $4.00 to $5.00. On average, they expect ZIOPHARM Oncology's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology
or view top-rated stocks among Wall Street analysts.

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the following people:
  • Mr. Zuie-Chin Huang M.B.A., Exec. Chairman (Age 55, Pay $22.28k)
  • Ms. Heidi M. Hagen, Interim CEO, Principal Exec. Officer & Director (Age 52, Pay $69k)
  • Dr. Eleanor de Groot, Exec. VP & GM of Cell Therapy (Age 52, Pay $488.98k)
  • Dr. Raffaele Baffa M.D., Ph.D., Chief Medical Officer (Age 60, Pay $242.83k)
  • Mr. Timothy M. Cunningham M.B.A., CPA, Interim CFO & Principal Financial Officer (Age 59)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 65)
  • Ms. Lynn M. Ferrucci, Exec. VP of HR, Facilities, Admin. & IT
  • Dr. Adam D. Levy M.B.A., Ph.D., Exec. VP of Investor Relations & Corp. Communications
  • Dr. David M. Mauney M.D., Consultant (Age 52)
  • Ms. Jill Buck, Exec. VP & GM of Gene Therapy (Age 47)

Who are some of ZIOPHARM Oncology's key competitors?

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), (CELG), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.11%), Oppenheimer & Co. Inc. (0.08%), Magnolia Capital Advisors LLC (0.05%) and Cutler Group LP (0.00%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield.
View institutional ownership trends for ZIOPHARM Oncology

Which institutional investors are buying ZIOPHARM Oncology stock?

ZIOP stock was purchased by a variety of institutional investors in the last quarter, including Magnolia Capital Advisors LLC, Oppenheimer & Co. Inc., Alliancebernstein L.P., and Cutler Group LP.
View insider buying and selling activity for ZIOPHARM Oncology
or or view top insider-buying stocks.

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $2.24.

How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology has a market capitalization of $482.76 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-79,980,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does ZIOPHARM Oncology have?

ZIOPHARM Oncology employs 103 workers across the globe.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is

Where are ZIOPHARM Oncology's headquarters?

ZIOPHARM Oncology is headquartered at ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.